Company / Shareholders' Equity
NovaBay Pharmaceuticals, Inc. Shareholders' Equity History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
-$129.0K
FY2024
5-year range
-$129.0K / $12.3M
FY2020-FY2024
Trend
-103.9%
vs FY2023
Sector context
#194 of 215
Health Care
What the data says
NovaBay Pharmaceuticals, Inc. reports negative total equity of -$129,000 in FY2024. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-$129,000 in FY2024.
Declined from $11M to -$129,000 over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 10% in Health CareTop 90% of 215This company -$129.0K Sector average $2.6B
▼
-100.0% below sector average
Key checks
Key Insights
- In FY2024, shareholders' equity decreased 103.9% year-over-year.
- Ranks #194 out of 215 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2020.
- Lowest shareholders' equity in the period was in FY2015.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.51 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$129.0K | -103.9% |
| FY2023 | $3.3M | -68.6% |
| FY2022 | $10.6M | +3.8% |
| FY2021 | $10.2M | -17.4% |
| FY2020 | $12.3M | +1166.0% |
| FY2019 | $973.0K | -80.4% |
| FY2018 | $5.0M | +91.0% |
| FY2017 | $2.6M | -63.5% |
| FY2016 | $7.1M | +239.3% |
| FY2015 | -$5.1M | -375.9% |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026